Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 4/20 | 0.32 |
| ▸ | DRD4 | P21917 | 2/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2694746 | 0.81 | PGK1 (0.33) | PGK1 | |
| Hydrochloric Acid SCHEMBL27775365 | 0.79 | TSHR (0.36) | PGK1TSHRCYP3A4RECQLAR | |
| SCHEMBL28315214 | 0.77 | DYRK1A (0.38) | PGK1TSHRCYP3A4EGFRERBB2 | |
| SCHEMBL29468705 | 0.77 | DYRK1A (0.38) | PGK1TSHRCYP3A4EGFRERBB2 | |
| SCHEMBL16906533 | 0.73 | AR (0.43) | TSHRAREGFR | |
| SCHEMBL24743198 | 0.72 | MAPKAPK2 (0.36) | PGK1TSHRCYP3A4ARADORA2A | |
| SCHEMBL28286735 | 0.70 | ABCG2 (0.43) | PGK1RECQLAREGFR | |
| Hydrochloric Acid SCHEMBL27701462 | 0.69 | TSHR (0.47) | PGK1TSHRADORA2AADORA1 | |
| SCHEMBL1642132 | 0.68 | AR (0.49) | AR | |
| SCHEMBL152425 | 0.68 | AR (0.40) | TSHRAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104710420-B | Azabicyclic formula compound or its salt, containing its medicine, compositions and application | 大鹏药品工业株式会社 | 2016-07-27 | — | — | CN | disclosed |
| US-9273045-B2 | Azabicyclo compound and salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-03-01 | — | — | US | disclosed |
| EP-2452940-B1 | AZABICYCLO COMPOUND AND SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-20140303162-A1 | AZABICYCLO COMPOUND AND SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-10-09 | — | — | US | disclosed |
| US-8779142-B2 | Azabicyclo compound and salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-07-15 | — | — | US | disclosed |
| CN-102471335-A | Azanebicyclic compound or salt thereof | TAIHO PHARMACEUTICAL CO LTD | 2012-05-23 | — | — | CN | disclosed |
| EP-2452940-A1 | AZABICYCLO COMPOUND AND SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2012-05-16 | — | — | EP | disclosed |
| US-20120108589-A1 | AZABICYCLO COMPOUND AND SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303162-A1 | AZABICYCLO COMPOUND AND SALT THEREOF | HSP90AB1, HSP90AB2P, HSP90AA1 | PGK1 4670/4885TSHR 1559/4885CYP3A4 2098/4885 |
| US-20120108589-A1 | AZABICYCLO COMPOUND AND SALT THEREOF | HSP90AB1, HSP90AB2P, HSP90AA1 | PGK1 4670/4885TSHR 1559/4885CYP3A4 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.